Checkpoint Therapeutics Inc. (NASDAQ:CKPT) and Kezar Life Sciences Inc. (NASDAQ:KZR) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Checkpoint Therapeutics Inc.	3.51M	29.56	36.37M	-1.16	0.00
Kezar Life Sciences Inc.	N/A	0.00	23.17M	-1.05	0.00

Demonstrates Checkpoint Therapeutics Inc. and Kezar Life Sciences Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both businesses.

	Net Margins	Return on Equity	Return on Assets
Checkpoint Therapeutics Inc.	-1,036.18%	-139%	-104.3%
Kezar Life Sciences Inc.	0.00%	0%	0%

Liquidity

Checkpoint Therapeutics Inc.’s Current Ratio is 3.5 while its Quick Ratio is 3.5. On the competitive side is, Kezar Life Sciences Inc. which has a 32.9 Current Ratio and a 32.9 Quick Ratio. Kezar Life Sciences Inc. is better positioned to pay off short and long-term obligations compared to Checkpoint Therapeutics Inc.

Insider and Institutional Ownership

Checkpoint Therapeutics Inc. and Kezar Life Sciences Inc. has shares owned by institutional investors as follows: 11.2% and 49.1%. 9.4% are Checkpoint Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 12.65% of Kezar Life Sciences Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Checkpoint Therapeutics Inc.	8.9%	-20.1%	36.3%	-19.9%	-27.32%	68.13%
Kezar Life Sciences Inc.	-0.34%	13.07%	-20.02%	17.87%	0%	-14.19%

For the past year Checkpoint Therapeutics Inc. has 68.13% stronger performance while Kezar Life Sciences Inc. has -14.19% weaker performance.

Summary

Kezar Life Sciences Inc. beats Checkpoint Therapeutics Inc. on 6 of the 9 factors.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.